Baird analyst Wesley Golladay downgrades Getty Realty (NYSE:GTY) from Outperform to Neutral and announces $34 price target.
Moleculin Granted FDA Fast Track Designation Of WP1122 For The Treatment Of Glioblastoma Multiforme
Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses,
